A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Completed · Phase 3 · NCT04657003
Conditions: Type 2 Diabetes, Overweight, Obesity
At a glance
- Research payments reported, 2025
- $10,120
- U.S. investigators named
- 2
- Sites paid
- 1
- Planned or actual enrollment
- 938
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Placebo (other)
- Dates
- Started 2021-03-29; completion 2023-04-10
- Results posted
- Yes
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
From ClinicalTrials.gov, last updated 2024-04-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $10,120 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Margaret E. Rhee, MD OB-GYN (Obstetrics & Gynecology) · Akron, OH
- David Fried, MD Internal Medicine · East Greenwich, RI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $10,120
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.